ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1527

Acute Effects of Intravenous Iloprost on Finger Power Doppler Ultrasound in Scleroderma Patients

Sofia Testoni1, Luca Magnani2, Caterina Tomassini3, Alessia Laneri3, Carlo Salvarani4 and PIERLUIGI MACCHIONI2, 1Università degli Studi di Modena e Reggio Emilia, San Giovanni in Persiceto, Italy, 2Azienda USL -IRCCS di Reggio Emilia, Reggio Emilia, Italy, 3Università degli Studi di Modena e Reggio Emilia, Modena, Italy, 4Azienda USL -IRCCS di Reggio Emilia and Università di Modena e Reggio Emilia, Reggio Emilia, Italy

Meeting: ACR Convergence 2023

Keywords: Peripheral Vascular Disease, Raynaud's phenomenon, Scleroderma, Ulcers, Ultrasound

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: (1513–1533) Systemic Sclerosis & Related Disorders – Clinical Poster II: Clinical Trial, Treatment & Intervention

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: So far few studies explored ultrasound (US) as a tool to assess vascular subcutaneous involvement in patients affected by systemic sclerosis (SSc). We aim to evaluate the acute vascular effects of intravenous iloprost (ILO) infusion by power Doppler US (PDUS) examination at periungual (PU) and finger pulp (FP) subcutaneous areas in a consecutive series of SSc patients.

Methods: Seventy-seven consecutive observations were done in 38 SSc patients (ACR/EULAR criteria). FP and PU vascularization of the 1st, 2nd, and 3rd finger of the dominant hand were evaluated before and after ILO infusion (dosage 0.5-2.0 ng/kg/min for 4-6 hours) using an Esaote MylabClassC, (Genoa, Italy) machine equipped with a 22-8 Mhz multifrequency linear probe. The image with the highest presence of PD signal at PU and FP for each finger was scored according to a semiquantitative 0-5 scale (0 = no signal, 5 = signal of healthy controls) and summed up to obtain a total patient PD score (TotS). Single finger PU PD scores were summed to obtain total PU PD score (TotPU). Single finger FP PD scores were summed to obtain total FP PD score (TotFP). Values before and after ILO treatment were compared by T-test for paired samples. No improvement in TotS was defined as a difference between T1 and T0 observation ≤ 0; improvement if the difference between T1 and T0 was 1. Clinical demographic and US data entered in a multivariate logistic regression analysis to evaluate factors predictive of TotS improvement.

Results: Clinical and laboratory features of the enrolled patients are reported in Table 1. The effects of ILO infusion on total PD scores are reported in Table 2. TotS was 9.43±6.34 at T0 and increased to 16.1±6.6 after treatment (p= < 0.001). TotS improved in 60 observations, while in 17 there was no variation or worsening. TotPU was 5.21±3.37 at T0 and increased to 9.17±3.7 after treatment (p= < 0.001). TotFP was 4.22±3.75 at T0 and increased to 6.9±4.22 at T1 (p= < 0.001). At multivariate logistic regression analysis concomitant therapy with calcium channel blockers (CCB) was predictive of PD total score improvement > 0 (OR 4.53; 95% CI 1.14-18.1 p=0.032) and concomitant pulmonary arterial hypertension (HAP) was associated to lack of response (OR 0.27; 95% CI 0.08-0.94 p=0.04).

Conclusion: PDUS examination of the PU and FP area can demonstrate an ILO acute vascular effect in SSc patients. Therapy with CCB and presence of HAP impact on PD score improvement.

Supporting image 1

Table 1. Demographic, clinical and laboratory characteristics of the 38 patients. SD: standard deviation; ILD: interstitial lung disease; HAP: pulmonary arterial hypertension; ERA: endothelin receptors antagonists; CCB: calcium channel blockers; PDE5i: Phosphodiesterase type 5 inhibitors; ENA: extractable nuclear antigen; ACA: Anti-centromere antibody.

Supporting image 2

Table 2. Values of Total PD score of the 77 observations before and after iloprost infusion. SRM = Standardized Response Mean (< 0.20 = trivial, 0.20-0.40 = small, 0.40-0.80 = moderate; > 0.80 = good).


Disclosures: S. Testoni: None; L. Magnani: None; C. Tomassini: None; A. Laneri: None; C. Salvarani: None; P. MACCHIONI: None.

To cite this abstract in AMA style:

Testoni S, Magnani L, Tomassini C, Laneri A, Salvarani C, MACCHIONI P. Acute Effects of Intravenous Iloprost on Finger Power Doppler Ultrasound in Scleroderma Patients [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/acute-effects-of-intravenous-iloprost-on-finger-power-doppler-ultrasound-in-scleroderma-patients/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/acute-effects-of-intravenous-iloprost-on-finger-power-doppler-ultrasound-in-scleroderma-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology